IN8bio, Inc. to Post Q1 2024 Earnings of ($0.15) Per Share, Zacks Small Cap Forecasts (NASDAQ:INAB)

IN8bio, Inc. (NASDAQ:INAB) – Equities research analysts at Zacks Small Cap issued their Q1 2024 earnings estimates for IN8bio in a research note issued on Monday, April 22nd. Zacks Small Cap analyst J. Vandermosten forecasts that the company will post earnings per share of ($0.15) for the quarter. The consensus estimate for IN8bio’s current full-year earnings is ($0.70) per share. Zacks Small Cap also issued estimates for IN8bio’s Q2 2024 earnings at ($0.15) EPS, Q3 2024 earnings at ($0.15) EPS, Q4 2024 earnings at ($0.13) EPS, FY2024 earnings at ($0.58) EPS, FY2025 earnings at ($0.59) EPS and FY2026 earnings at ($0.60) EPS.

IN8bio (NASDAQ:INAB) last issued its earnings results on Thursday, March 14th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.05).

Several other research analysts also recently commented on INAB. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 target price on shares of IN8bio in a research note on Wednesday, April 10th. Laidlaw assumed coverage on shares of IN8bio in a research note on Monday, March 18th. They issued a “buy” rating and a $7.50 target price on the stock.

IN8bio Price Performance

Shares of NASDAQ INAB opened at $1.04 on Wednesday. The company has a quick ratio of 4.57, a current ratio of 4.57 and a debt-to-equity ratio of 0.02. IN8bio has a 52 week low of $0.65 and a 52 week high of $3.95. The firm’s fifty day moving average is $1.13 and its 200 day moving average is $1.16.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Texas Capital Bank Wealth Management Services Inc increased its position in IN8bio by 85.2% during the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 78,624 shares of the company’s stock valued at $109,000 after purchasing an additional 36,179 shares during the period. Rock Creek Group LP increased its position in IN8bio by 98.3% during the 3rd quarter. Rock Creek Group LP now owns 151,314 shares of the company’s stock valued at $157,000 after purchasing an additional 75,000 shares during the period. Voss Capital LLC increased its position in IN8bio by 11.7% during the 3rd quarter. Voss Capital LLC now owns 511,584 shares of the company’s stock valued at $532,000 after purchasing an additional 53,708 shares during the period. Finally, AIGH Capital Management LLC purchased a new position in IN8bio during the 4th quarter valued at $5,216,000. 92.05% of the stock is owned by hedge funds and other institutional investors.

About IN8bio

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.